ArticleJournal of immunology (Baltimore, Md. : 1950)2008
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.Cancer immunology, immunotherapy : CII · 2012Trial
- Research and application of hydrostatic high pressure in tumor vaccines (Review).Oncology reports · 2021Review
- Prognostic significance of CD4 and interleukin-22 expression in pancreatic cancer.International journal of clinical and experimental pathology · 2017Article
- Article
- Article
- Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Frontiers in immunology · 2013Article
- A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.Cancer gene therapy · 2012Article
- Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.Human gene therapy · 2010Article
- In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Tumor regulatory T cells potently abrogate antitumor immunity.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Adoptive immunotherapy of cancer using CD4(+) T cells.Current opinion in immunology · 2009Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Administration of anti-CD25 mAb before an aggressive murine breast tumor inoculation provoked effective antitumor immunity. Compared with CD4(+) T cells purified from anti-CD25 mAb-pretreated mice that did not reject tumor, CD4(+) T cells purified from anti-CD25 mAb-pretreated mice that rejected tumor stimulated by dendritic cells (DCs) produced more IFN-gamma and IL-2, and less IL-17 in vitro, and ignited protective antitumor immunity in vivo in an adoptive transfer model. Tumor Ag-loaded DCs activated naive CD8(+) T cells in the presence of these CD4(+) T cells in vitro. Tumor Ag and adoptively transferred CD4(+) T cells were both required for inducing a long-term tumor-specific IFN-gamma-producing cellular response and potent protective antitumor activity. Although adoptively transferred CD4(+) T cells ignited effective tumor-specific antitumor immunity in wild-type mice, they failed to do so in endogenous NK cell-depleted, Gr-1(+) cell-depleted, CD40(-/-), CD11c(+) DC-depleted, B cell(-/-), CD8(+) T cell-depleted, or IFN-gamma(-/-) mice. Collectively, the data suggest that adoptively transferred CD4(+) T cells orchestrate both endogenous innate and adaptive immunity to generate effective tumor-specific long-term protective antitumor immunity. The data also demonstrate the pivotal role of endogenous DCs in the tumor-specific protection ignited by adoptively transferred CD4(+) T cells. Thus, these findings highlight the importance of adoptively transferred CD4(+) T cells, as well as host immune components, in generating effective tumor-specific long-term antitumor activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.